Mauro Romano

Mauro Romano

Auto-generated profile, based on publicly available information

Mauro Romano

Department of Cardiovascular Surgery and Transcatheter Heart and Vascular Therapies, Institut Cardiovasculaire Paris Sud, Institut Hospitalier Jacques Cartier, Massy, France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in World Journal of Cardiology
Verified
Journal Article
Open access
FSFadi J Sawaya
Fadi J Sawaya
MSMarco Spaziano
Marco Spaziano
TLThierry Lefevre
Thierry Lefevre
ARAndrew Roy
Andrew Roy
PGPhilippe GAROT
Philippe GAROT
BCBernard Chevalier
Bernard Chevalier
Comparison between the SAPIEN S3 and the SAPIEN XT transcatheter heart valves: A single-center experience

28 November 2019 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Closed access
MRMauro Romano
Mauro Romano
ADAndrea Daprati
Andrea Daprati
Guglielmo SaittoGuglielmo Saitto
Guglielmo Saitto
FTFrancesco Tizzano
Francesco Tizzano
DHDaniel Le Houérou
Daniel Le Houérou
AGAndrea Garatti
Andrea Garatti
OBJECTIVES: Transcatheter aortic valve implantation with a transaortic approach (TAo-TAVI) is an alternative to transapical or femoral access. We studied the procedural and midterm efficacy and safety of TAo-TAVI with Edwards Sapien XT and Medtronic CoreValve devices. METHODS: Among 901 patients receiving TAVI since 2006, 265 consecutive patients underwent TAo-TAVI between January 2011 and September 2014. Procedural and midterm results were evaluated according to Valve Academic Research Consortium-2 criteria. RESULTS: The mean age was 83 ± 5 years. Sapien XT and CoreValve were used in 191 (72.1%) and 74 (27.9%) patients, respectively. Full sternotomy made elective concomitant off-pump coronary artery bypass grafting possible in 38 patients (14.3%) with severe coronary artery disease unsuitable for percutaneous coronary intervention. The device success rate was 95.5%. Postprocedural paravalvular leak ≥2/4 was observed in 16 patients (6.4%). Emergency open chest surgery was required in 10 patients (3.8%) (3 aortic dissections, 3 valve embolizations, 2 LMCA occlusions, 1 aortic annulus rupture and 1 aortic rupture). Cerebrovascular accidents occurred in 3 patients (1.1%). Transfusions ≥4 units were required in 36 patients (13.6%). New pacemakers were implanted in 26 patients (9.8%). Thirty-day and 1-year mortality were 8.7% and 16.2%, respectively. Mean follow-up duration was 24 ± 6 months. At 3 years, freedom from all-cause death was 80% ± 4%. New York Heart Association class <III included 81% (n = 172) of patients alive and without prosthetic echocardiographic dysfunction at follow-up (mean gradient 10.5 ± 5.6 mmHg). CONCLUSION: The TAo-TAVI approach confirms its safety and effectiveness with satisfactory procedural and midterm outcomes with both currently available devices.